fbpx
QQQ
+ 0.00
299.01
+ 0%
DIA
+ 0.00
299.22
+ 0%
SPY
+ 0.00
363.71
+ 0%
TLT
+ 0.00
160.22
+ 0%
GLD
+ 0.00
167.77
+ 0%

Organigram Invests In Hyasynth Biologicals, Parts Ways With Executives

October 23, 2020 10:50 am
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More

Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI) has invested an additional $2.5 million in a private biotechnology company Hyasynth Biologicals Inc.

It’s the second tranche of financing under the $10 million debenture purchase deal between Organigram Inc. – a subsidiary of the Moncton, New Brunswick-based company – and Hyasynth.

In addition, Organigram said it retains the right to buy Hyasynth’s cannabinoid or cannabinoid related production at a 10% discount to the wholesale market price in ten years following the onset of Hyasynth’s commercial production.

In September 2018, the company advanced $5 million to Hyasynth. In addition, it has an option to buy a remaining $2.5 million of convertible secured debentures.

The financing comes on the heels of the Hyasynth’s first sale of cannabidiol (CBD) produced and extracted from yeast.

Hyasynth – launched in 2014 – is the Montreal, Canada-based biotechnology company that utilizes fermentation in its biosynthesis process resulting in THC, CBD, CBG, and rare cannabinoids production.

“We believe biosynthesis has the potential to redefine the cannabinoid production landscape by setting a scalable and reliable platform of supply that cannabis producers and pharmaceutical companies can leverage for success,” Organigram CEO Greg Engel said Friday.

Executive Shake-Ups

Meanwhile, Organigram also revealed its Vice President of Marketing Julie Chamberlain is leaving the company to serve as General Manager in a non-competing industry.

In addition, Cameron Bishop, Vice President of Public Affairs and Stakeholder Relations, also opted to part ways with the company to pursue other opportunities.

In July, the company laid off 25% of its workforce, ahead of reporting a 27% year-over-year decline in revenue. For the third quarter, its revenue amounted to $18 million.


Related Articles

The Week In Cannabis: Stocks Skyrocket As Markets Rise, Jay-Z's New Mega Venture And More

In a four-day week where markets were on the rise, cannabis stocks proved to be big winners. Late Friday, stocks surged on news that a federal marijuana legalization bill will get a congressional vote next week. During the holiday week: read more

CBD For Dogs: Do Vets Recommend It For Your Pets?

This article was originally published on WeedWeek, and appears here with permission. read more

Pure Sunfarms Inks Supply Deal With Shoppers Drug Mart

Pure Sunfarms opted to supply Shoppers Drug Mart Inc's customers with its cannabis products. The Village Farms International Inc. (NASDAQ: VFF) (TSX: VFF) subsidiary teamed up with the Canadian retail pharmacy chain to provide consumers with Pure Sunfarms' dried flower products. read more

Cannabis Movers & Shakers: Cannabis Growth Opportunity, Bhang, CanaFarma Hemp, Amfil Technologies

Here is a summary of the latest company shakeups within the cannabis industry. 3 Execs Exit Cannabis Growth Opportunity Investment company Cannabis Growth Opportunity Corporation (CSE: CGOC) has parted ways with several executives. read more

Earnings Update: Vireo, Rubicon, Flower, Planet 13, Driven Deliveries, Decibel, Pure Harvest

Vireo Health Revenue Spikes, New Stores To Open By Q1 2021 read more